Caris Life Sciences, Inc. (CAI)

NASDAQ: CAI · USD

$35.5

+1.82 (+5.4%)· Recorded snapshot

Market cap	10B
Revenue (ttm)	989.6M
Net income (ttm)	105.1M
EPS (ttm)	$0.37
Shares out	282.6M
P/E (trailing)	95.7x
P/E (forward)	129.6x
Volume	3,795,883

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 989.6M
Net income (ttm): 105.1M
EPS (ttm): $0.37
P/E (trailing): 95.7x
P/E (forward): 129.6x
Market cap: 10B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E129.6

P25 13.4P50 20.2P75 35.7

Trailing P/E95.7

P25 15.4P50 25.8P75 43.5

ROE20.1

P25 -113.8P50 -46.5P75 -0.9

ROIC10

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All CAI indicators

Market & fundamental data

Available fields

218

Groups with data

Currency

USD

Showing 218 of 218 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002019410
Company name	Caris Life Sciences, Inc.
Country	United States
Country code	US
CUSIP number	142152107
Earnings date	2026-11-04
Earnings time	amc
Employees	1,846
Employees change	77
Employees growth	4.35%
Enterprise value	$9.7B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2008
Industry	Biotechnology
IPO date	2025-06-18
Is primary listing	Yes
Is SPAC	No
ISIN number	US1421521071
Last 10-K release date	2026-03-03
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$10B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$35.50
Price currency	USD
Sector	Healthcare
SIC code	8071
Stock price date	2026-10-28
Symbol	CAI
U.S. state	Texas
Website	https://www.carislifesciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	98.6x
Earnings yield	1.05%
EV/Earnings	94.01x
EV/EBIT	64.49x
EV/EBITDA	56.79x
EV/FCF	79.73x
EV/Sales	9.99x
FCF / EV yield	1.25%
FCF yield	1.21%
Forward EV/Sales	8.86x
Forward P/E	129.61x
Forward P/S	9.16x
Graham number	4.1808
Graham upside	-88.44%
P/(FCF - SBC) ratio	173.76x
P/(OCF - SBC) ratio	98.84x
P/B ratio	16.08x
P/E ratio	95.68x
P/FCF ratio	82.48x
P/OCF ratio	60.66x
P/S ratio	10.33x
Price / tangible book value	17.86x
Price/EBITDA ratio	58.75x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.49%
EBITDA margin	17.59%
FCF margin	12.53%
Gross margin	69.85%
Operating margin	15.49%
Pretax margin	10.61%
Profit margin	10.62%
Profit per employee	$56,953
Revenue per employee	$536,081
ROA	8.77%
ROCE	14.76%
ROE	20.13%
ROIC	10%
SBC / revenue	6.58%
Tax / revenue	-0.01%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
FCF growth (Q)	8.47%
FCF growth (QoQ)	-71.59%
Gross profit growth	140.42%
Gross profit growth (Q)	57.98%
Net income growth quarters	4
Net income growth years	0
OCF growth (Q)	290.74%
OCF growth (QoQ)	-13.38%
Revenue growth	85.37%
Revenue growth (Q)	45.38%
Revenue growth (QoQ)	21.99%
Revenue growth quarters	6
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-44.6M
Depreciation and amortization	$20.8M
EBIT	$153.3M
EBITDA	$174M
EPS	$0.37
FCF per share	$0.44
Financing cash flow	$-53.8M
Free cash flow	$124M
Free cash flow minus SBC	$58.8M
Gross profit	$691.2M
Income taxes	$-111,000
Investing cash flow	$-144.7M
Net borrowing	$-13M
Net cash flow	$-29.9M
Net income	$105.1M
Operating cash flow minus SBC	$103.4M
Operating income	$153.3M
Revenue	$989.6M
Stock-based compensation	$65.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.79
Book value per share	$2.09
Debt / EBITDA	2.45
Debt / equity	0.76
Debt / FCF	3.65
Goodwill	$19.3M
Interest coverage	3.27
Long-term assets	$171.8M
Long-term liabilities	$446.4M
Net cash (debt)	$340.7M
Net cash / market cap	3.33%
Net cash growth	12.74%
Net debt / EBITDA	-1.96
Net debt / equity	-0.58
Net debt / FCF	-2.75
Piotroski F-Score	5
Property, plant and equipment	$95.7M
Shareholders' equity	$591.7M
Tangible book value	$572.4M
Tangible book value per share	$2.03
Total assets	$1.2B
Total cash	$793.1M
Total debt	$452.4M
Total liabilities	$637.9M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.91
Current assets	$1.1B
Current liabilities	$191.4M
Current ratio	5.53
Inventory turnover	3.63
Net working capital	$79.8M
Quick ratio	4.75
Working capital	$866.4M
Working capital turnover	1.23

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-559.05%
Dividend yield	0%
Shareholder yield	-559.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$21.52
1D price change	5.42%
1M price change	12.29%
1M total return	12.29%
1W price change	15.43%
1W total return	15.43%
1Y price change	18.71%
1Y return CAGR	18.73%
1Y total return	18.71%
20-day SMA	$30.53
200-day SMA	$21.49
3M price change	129.75%
3M total return	129.75%
50-day SMA	$28.71
50-day SMA vs 200-day SMA	50over200
52-week high	$36.50
52-week high date	2026-10-28
52-week low	$14.19
52-week low date	2026-05-13
6M price change	80.18%
6M total return	80.18%
All-time high	$42.50
All-time high date	2025-08-22
All-time low	$14.19
All-time low date	2026-05-13
Average true range (ATR)	$1.88
Average volume	3.5M
Beta (1Y)	2.32
Beta (2Y)	2.08
Change from 52-week high	-2.75%
Change from 52-week low	150.14%
Change from all-time high	-15.51%
Change from all-time low	153.07%
Change from open	5.8%
Day's gap	-0.36%
Dollar volume	$134.7M
High price	$36.33
Low price	$33.55
Monthly RSI	64.66
Open price	$33.55
Position in 52-week range	69.96%
Premarket change	0.39%
Premarket close	$33.67
Premarket price	$33.80
Premarket volume	6.7K
Previous close	$33.67
Price vs 150-day SMA	66.89%
Price vs 20-day SMA	17.64%
Price vs 200-day SMA	67.11%
Price vs 50-day SMA	25.09%
Relative volume	1.07
Return from IPO open	34%
Return from IPO price	72.29%
RSI	72.12
Sharpe ratio	0.53
Sortino ratio	0.87
Volume	3.8M
Weekly RSI	70.83
YTD price change	33.1%
YTD total return	33.1%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	134.9M
Float percentage	47.72%
Shares change (QoQ)	0.12%
Shares change (YoY)	559.05%
Shares held by insiders	48.8%
Shares held by institutions	57.74%
Shares outstanding	282.6M
Short % of float	10.08%
Short % of shares	4.81%
Short ratio	2.7 days

Deeper analysis on CAI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CAI report

Is a complete CAI research report available?

No complete published report is available for Caris Life Sciences, Inc. (CAI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Caris Life Sciences, Inc. (CAI)

Price

Financial snapshot

Fair-value bridge

Latest news · CAI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CAI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CAI

Frequently asked questions